ReviewNature reviews. Clinical oncology2013
Validation and clinical utility of prostate cancer biomarkers.
Review in Nature reviews. Clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Guideline
- An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.Cancer discovery · 2018Trial
- Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors.Physics in medicine and biology · 2016Trial
- Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men.Theranostics · 2014Trial
- Epithelial-Mesenchymal Plasticity in Cancer: Transcriptional Regulation, Biomarker Challenges, and Emerging Therapeutic Opportunities.Cell biochemistry and function · 2026Review
- Review
- 20 years of taxane therapy in prostate cancer - the past, present and future.Nature reviews. Urology · 2026Review
- Bone scan index rise prior to osteonecrosis of the jaw with bone-modifying agents in prostate cancer.BJUI compass · 2026Article
- Circulating tumor cell-based PSMA and PSA expression as a predictive and prognostic tool in prostate cancer.Translational cancer research · 2025Article
- The Circulating Biomarkers League: Combining miRNAs with Cell-Free DNAs and Proteins.International journal of molecular sciences · 2024Review
- Sorafenib combined with tarexib for first-line treatment of unresectable hepatocellular carcinoma and its predictive role and correlation with PD-L1 CTCs.Frontiers in oncology · 2024Article
- Feasibility study of expressing epcam + /vimentin + CTC in prostate cancer diagnosis.Journal of cancer research and clinical oncology · 2023Article
- Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.British journal of cancer · 2022Review
- Combinatorial Power of cfDNA, CTCs and EVs in Oncology.Diagnostics (Basel, Switzerland) · 2022Review
- Circulating tumor cells in the early detection of human cancers.International journal of biological sciences · 2022Review
- The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.Frontiers in oncology · 2022Article
- Two-Step Acoustophoresis Separation of Live Tumor Cells from Whole Blood.Analytical chemistry · 2021Article
- Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers.Clinical & experimental metastasis · 2021Article
- Effect of the versatile bifunctional chelator AAZTAEJNMMI radiopharmacy and chemistry · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To improve future drug development and patient management for patients with castration-resistant prostate cancer (CRPC), surrogate biomarkers that are linked to relevant outcomes are urgently needed. A biomarker must be measurable, reproducible, linked to relevant clinical outcomes, and demonstrate clinical utility. This area is rapidly evolving, with recent trials in patients with CRPC incorporating the detection of circulating tumour cells (CTCs), imaging, and patient-reported outcome biomarkers. We discuss the framework for the development of biomarkers for CRPC, including different categories and contexts of use. We also highlight the requirements of analytical validation, the sequence of trials needed for clinical validation and regulatory approval, and the future outlook for imaging and CTC biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.